Gary Goldstein, MD
Pediatrics · Palm Harbor, FLNPI 1215995345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 844 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 9.8% — the pattern of someone who eats at a lot of different presentations. Among pediatrics clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 844 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- Pfizer$968
- Amarin Pharma, Inc.$906
- plus $9K from 51 others
Across 558 payments — averaging $2147.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akcea Therapeutics, Inc.$350K
- Eli Lilly$283K
- Sanofi US Services Inc.$135K
- Bayer$114K
- AstraZeneca$110K
- AbbVie$90K
- plus $116K from 6 others
What the payments were for
- Food & beverage$16,34799%
- Education$1191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$331
- NURTEC ODT$125
- VRAYLAR$125
- QULIPTA$110
- UBRELVY$110
How this compares
$16,467 in reported general payments places this provider in the 95th percentile of 3,964 pediatrics providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 348 | $394,914 |
| EliquisApixaban | 92 | $102,737 |
| OzempicSemaglutide | 50 | $76,955 |
| FarxigaDapagliflozin Propanediol | 34 | $43,162 |
| TrulicityDulaglutide | 31 | $39,257 |
| JardianceEmpagliflozin | 36 | $37,666 |
| XareltoRivaroxaban | 30 | $31,206 |
| Repatha SureclickEvolocumab | 46 | $30,931 |
| NucyntaTapentadol Hcl | 13 | $30,541 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $28,484 |
| Tresiba Flextouch U-200Insulin Degludec | 31 | $27,215 |
| JanuviaSitagliptin Phosphate | 33 | $25,960 |
| ProliaDenosumab | 11 | $18,763 |
| LinzessLinaclotide | 11 | $16,072 |
| MyrbetriqMirabegron | 17 | $15,261 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,537 | $434,171379 claims |
| PfizerEliquis, Abrysvo, Paxlovid | $968 | $111,326146 claims |
| Novo NordiskOzempic, Rybelsus | $1,079 | $87,43561 claims |
| AstraZenecaFarxiga, Brilinta | $1,267 | $58,01555 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Shingrix | $207 | $46,46589 claims |
| Boehringer IngelheimJardiance | $729 | $37,66636 claims |
| MerckJanuvia, Belsomra | $404 | $32,04747 claims |
| Johnson & JohnsonXarelto | $303 | $31,20630 claims |
| AbbVieLinzess, Synthroid | $1,622 | $19,54549 claims |
| AmgenProlia | $852 | $18,76311 claims |
| Astellas Pharma US IncMyrbetriq | $458 | $15,26117 claims |
| NovartisEntresto | $519 | $10,43414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,964 pediatrics providers in Florida.
Other pediatrics in Palm Harbor
- Jorge Lujan-ZilbermanTampa$378K
- Bonnie SmeryageHollywood$153K
- Patricia DeanMiami$92K
- Ryan CantvilleJacksonville$87K
- Christina CanodyTampa$87K
- Sofia MirandaMiami$67K
- Jose HerreraMiami$61K
- Joanna DavisMiami$59K
- Anastasia Albanese-O'neillGainesville$42K
- Monica ShahBrandon$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.